Late-stage biotech developing muscle-targeted therapeutics for heart failure and neurodegeneration
Cytokinetics is a public biotech company engineering small-molecule drugs to modulate muscle function in diseases where contractility is compromised—heart failure, amyotrophic lateral sclerosis, and hypertrophic cardiomyopathy. The tech stack (Tableau, SageMaker, PostgreSQL, Python, AWS, GCP, Veeva, Medidata Rave) reflects a hybrid clinical-analytics operation, though hiring momentum is distributed across research, healthcare, and operations rather than concentrated in any single function, suggesting a company scaling manufacturing, regulatory, and supply-chain capability alongside drug development.
Notable leadership hires: Regulatory Affairs Director, Medical Director, Marketing Lead, Compliance Director
Cytokinetics discovers and develops first-in-class muscle activators and next-in-class muscle inhibitors for diseases characterized by declining muscle performance. Founded in 1998 and headquartered in South San Francisco, the company operates as a public biopharmaceutical enterprise with 501–1,000 employees across the United States, Switzerland, the United Kingdom, France, Germany, Italy, and Spain. Active projects span clinical trial regulatory submissions, bioinformatic tool development for target discovery, GCP compliance infrastructure, and clinical supply chain systems deployment—reflecting the operational complexity of late-stage drug development and commercial preparation.
Cytokinetics uses Tableau, SageMaker, PostgreSQL, Python, AWS, GCP, Veeva (regulatory), Medidata Rave (clinical data), GitHub, SAS, and MicroStrategy. The mix indicates both clinical trial management and data analytics infrastructure.
South San Francisco, California. The company also operates hiring offices in Switzerland, the United Kingdom, France, Germany, Italy, and Spain.
Other companies in the same industry, closest in size